Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $6,063,599 | $4,876,022 | $7,786,424 | $5,655,376 |
| - Cash | $115,850 | $118,370 | $234,195 | $118,719 |
| + Debt | $1,505,798 | $1,499,248 | $1,506,100 | $876,674 |
| Enterprise Value | $7,453,547 | $6,256,900 | $9,058,329 | $6,413,331 |
| Revenue | $1,015,324 | $829,253 | $660,116 | $443,310 |
| % Growth | 22.4% | 25.6% | 48.9% | – |
| Gross Profit | $855,907 | $636,892 | $520,812 | $361,897 |
| % Margin | 84.3% | 76.8% | 78.9% | 81.6% |
| EBITDA | $656,539 | $451,947 | $315,506 | $259,041 |
| % Margin | 64.7% | 54.5% | 47.8% | 58.4% |
| Net Income | $444,091 | $281,594 | $202,129 | $402,710 |
| % Margin | 43.7% | 34% | 30.6% | 90.8% |
| EPS Diluted | 3.43 | 2.1 | 1.44 | 2.74 |
| % Growth | 63.3% | 45.8% | -47.4% | – |
| Operating Cash Flow | $479,064 | $388,571 | $240,110 | $299,440 |
| Capital Expenditures | -$10,696 | -$15,294 | -$4,810 | -$1,457 |
| Free Cash Flow | $468,368 | $373,277 | $235,300 | $297,983 |